Get Live Data

The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here. 

Less Ads, More Data, More Tools Register for FREE
GreenRoc Accelerates their World Class Project to Production as Early as 2028
GreenRoc Accelerates their World Class Project to Production as Early as 2028View Video

Latest Share Chat

  2. Share Prices
  3. Angle Share Price
  4. Angle Share News
  5. UK earnings, trading statements calendar - next 7 days

Pin to quick picksAngle Share News (AGL)

Angle Information

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.75
Bid: 15.50
Ask: 16.00
Change: -2.25 (-12.50%)
Spread: 0.50 (3.226%)
Open: 15.50
High: 16.50
Low: 15.50
Prev. Close: 18.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK earnings, trading statements calendar - next 7 days

Thu, 22nd Sep 2022 15:48

Friday 23 September 
Biffa PLCTrading Statement
European Opportunities Trust PLCFull Year Results
Investec PLCTrading Statement
Smiths Group PLCFull Year Results
TheWorks.co.uk PLCFull Year Results
Monday 26 September 
Atome Energy PLCHalf Year Results
Chapel Down Group PLCHalf Year Results
Concurrent Technologies PLCHalf Year Results
CPPGroup PLCHalf Year Results
Devolver Digital IncHalf Year Results
Dillistone Group PLCHalf Year Results
Finsbury Food Group PLCFull Year Results
Frenkel Topping Group PLCHalf Year Results
Immotion Group PLCHalf Year Results
Likewise Group PLCHalf Year Results
Microlise Group PLCHalf Year Results
Next Fifteen Communications PLCHalf Year Results
SpaceandPeople PLCHalf Year Results
XLMedia PLCHalf Year Results
Xpediator PLCHalf Year Results
Tuesday 27 September 
AG Barr PLCHalf Year Results
Animalcare Group PLCHalf Year Results
Billington Holdings PLCHalf Year Results
Boku IncHalf Year Results
Card Factory PLCHalf Year Results
Close Brothers Group PLCFull Year Results
Diaceutics PLCHalf Year Results
Digitalbox PLCHalf Year Results
ECSC Group PLCHalf Year Results
Ergomed PLCHalf Year Results
Ferguson PLCFull Year Results
FireAngel Safety Technology Group PLCHalf Year Results
GENinCode PLCHalf Year Results
Gresham House Energy Storage Fund PLCHalf Year Results
K3 Capital Group PLCFull Year Results
Instem PLCHalf Year Results
LifeSafe Holdings PLCHalf Year Results
Medica Group PLCHalf Year Results
Mission Group PLCHalf Year Results
Mortgage Advice Bureau PLCHalf Year Results
NAHL Group  PLCHalf Year Results
Origin Enterprises PLCFull Year Results
United Utilities Group PLCTrading Statement
Personal Group Holdings PLCHalf Year Results
S&U PLCHalf Year Results
Saga PLCHalf Year Results
Serica Energy PLCHalf Year Results
SSP Group PLCTrading Statement
tinyBuild IncHalf Year Results
Transense Technologies PLCFull Year Results
Yu Group PLCHalf Year Results
Wednesday 28 September 
1Spatial PLCHalf Year Results
AVI Japan Opportunity Trust PLCHalf Year Results
Avingtrans PLCFull Year Results
Blancco Technology Group PLCFull Year Results
boohoo Group PLCHalf Year Results
Everyman Media Group PLCHalf Year Results
Octopus Renewables Infrastructure Trust PLCHalf Year Results
Shepherd Neame LtdFull Year Results
Skillcast Group PLCHalf Year Results
SolGold PLCFull Year Results
Thursday 29 September 
Allergy Therapeutics PLCFull Year Results
Angle PLCHalf Year Results
Avation PLCFull Year Results
Bango PLCHalf Year Results
Cap-XX LtdHalf Year Results
Celadon Pharmaceuticals PLCHalf Year Results
Crestchic PLCHalf Year Results
Directa Plus PLCTrading Statement
McBride PLCFull Year Results
NAHL Group PLCHalf Year Results
Next PLCHalf Year Results
Novacyt SAHalf Year Results
Physiomics PLCFull Year Results
Synairgen PLCHalf Year Results
XLMedia PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
29 Aug 2019 09:12

Angle initiates main phase of ovarian cancer clinical study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.

Read more
22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

Read more
25 Jun 2019 08:16

Angle looks to strengthen balance sheet and extend runway via placement

(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.

Read more
21 Jun 2019 15:26

Angle upbeat on recent cancer research results

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has published results of work demonstrating that its 'Parsortix' system can be used as a liquid biopsy to investigate programmed death-ligand 1 (PD-L1) status in non small cell lung cancer (NSCLC) patients.

Read more
21 Jun 2019 12:56

Angle's Parsortix Successfully Investigates Immunotherapy Target

(Alliance News) - Angle PLC on Friday said its Parsortix system has been successfully used as a liquid biopsy to investigate an immunotherapy target in lung cancer.Shares in Angle were up a

Read more
5 Jun 2019 13:04

Angle's Parsortix And HyCEAD Ziplex Systems Identify Cancer In Study

LONDON (Alliance News) - Angle PLC on Wednesday announced positive results from a study evaluating the ability of its Parsortix and HyCEAD Ziplex platforms to test for ovarian cancer.The to

Read more
31 May 2019 09:53

Angle reveals positive results from latest Parsortix study

(Sharecast News) - Liquid biopsy company Angle announced positive results from its 'Parsortix' FDA clinical study for metastatic breast cancer on Friday.

Read more
26 Apr 2019 12:48

Angle's Parsortix system used in more groundbreaking research

(Sharecast News) - Liquid biopsy company Angle announced on Friday that its 'Parsortix' system has been utilised in further groundbreaking new cancer research, demonstrating the role of myeloid-derived suppressor cells (MDSCs) as part of large circulating tumor cell (CTC) clusters, which are 50x more likely to generate metastasis than single CTCs, for the first time.

Read more
26 Apr 2019 12:29

Angle's Parsortix System Used In Further "Groundbreaking" Research

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said its Parsortix system has been used in "groundbreaking" cancer research.The research showed the first the time

Read more
18 Apr 2019 11:35

US Cancer Centre Uses Angle's Parsortix System For Assessments

LONDON (Alliance News) - Angle PLC on Thursday said its ParsortixTM system was used by the University of Texas MD Anderson Cancer Center to develop a new technique for assessing the metastatic of

Read more
12 Apr 2019 15:25

Angle's Parsortix to be used in new Greece study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using its 'Parsortix' system, which could give advance warning of relapse in non small cell lung cancer (NSCLC).

Read more
12 Apr 2019 11:59

University Of Athens Cancer Study To Use Angle's Parsortix System

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said a "leading" customer has set up a multi-centre study using its Parsortix system.The study is being carried out

Read more
7 Mar 2019 13:09

Angle Enrols All 400 Patients In US Breast Cancer Study For Parsortix

LONDON (Alliance News) - Angle PLC on Thursday said it has completed enrolment for a US study of its Parsortix biopsy technology in metastatic breast cancer.All of the 400 subjects required

Read more
7 Mar 2019 09:35

Angle completes enrolment in Parsortix breast cancer study

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that enrolment for its 'Parsortix' FDA clinical study for metastatic breast cancer was now complete.

Read more
28 Feb 2019 13:30

Angle Enrolls First Patients In Ovarian Cancer Study

LONDON (Alliance News) - Angle PLC on Thursday said it has enrolled the first patients in an ovarian cancer verification study, after receiving ethics approval.The study will be divided a a

Read more
789101112131415

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.